Rheumatoid Arthritis - TNF Antagonists

• Abstract 693: [18f] FDG-PET Changes after 2 Weeks of Infliximab Treatment Correlate with Long-Term Clinical Outcome in Rheumatoid Arthritis Patients
• Abstract L17: Remission Rates in Subjects With Active Early Rheumatoid Arthritis - 1 Year Results of the COMET Trial: Combination of Methotrexate and Etanercept in Active Early Rheumatoid Arthritis
• Abstract 726: Efficacy and Safety of Etanercept 100 mg in Patients with Rheumatoid Arthritis who are Suboptimal Responders to Etanercept 50 mg
• Abstract 268: Anti-TNF Treatment with Adalimumab Reduces Hand Bone Loss in Early Rheumatoid Arthritis (RA): Explorative Analyses from the Premier Study

Certolizumab pegol

TNF inhibition is an effective therapy for patients with rheumatoid arthritis and other forms of inflammatory disease including psoriasis, psoriatic arthritis, and ankylosing spondylitis.  Currently available therapies include a soluble p75 TNF receptor:Fc construct, etanercept, a chimeric monoclonal antibody antibody, infliximab, and a fully human monoclonal antibody, adalimumab.  Certolizumab pegol (CZP) is a novel TNF inhibitor which is an antigen-binding domain of a humanized TNF antibody coupled to polyethylene glycol (PEG) to increase half-life, and thus is Fc-domain-free.  Two major phase III randomized placebo-controlled studies were presented at ACR 2007 with this compound in patients with rheumatoid arthritis that have were also presented at EULAR. The RAPID1 Study (Abstract 700) was a 52 week Phase III study of a lyophilized formulation of certolizumab in RA patients on background MTX.  The RAPID 2 Study (Abstract 696) was a 52 week Phase III study using a liquid formulation of the drug also in RA patients on background MTX.  In both studies patients received 400 mg weekly SQ or placebo x 3 doses.  Patients receiving drug were then randomized to receive 400 mg sq q2wk or 200 mg sq q 2wk, and patients on placebo continued placebo. New data presented at ACR included radiographic.

• Abstract 696: Liquid Formulation Certolizumab Pegol with Methotrexate Decreases Progression of Structural Joint Damage in Rheumatoid Arthritis Patients: The RAPID 2 Study
• Abstract 700: The Anti-TNF Certolizumab Pegol in Combination with Methotrexate is Significantly More Effective than Methotrexate Alone in the Treatment of Patients with Active Rheumatoid Arthritis: 1-Year Results from the RAPID 1 Study

Abatacept

• Abstract 699:Long-Term Efficacy and Safety of Abatacept through 3 Years of Treatment in Rheumatoid Arthritis Patients in the AIM and ATTAIN Trials

Rituximab

• Abstract 2088: Repeated Treatment Courses of Rituximab Produce Sustained Efficacy in Patients with Rheumatoid Arthritis and an Inadequate Response or Intolerance to One or More TNF Inhibitors
• Abstract 261: Immunoglobulin Levels and Infection Rates in Patients with Rheumatoid Arthritis (RA) Treated With Repeated Courses of Rituximab

Ofatumumab

• Abstract 2086: Ofatumumab, a Human CD20 Monoclonal Antibody, in the Treatment of Rheumatoid Arthritis: Early Results from an Ongoing, Double-Blind, Randomized, Placebo Controlled Clinical Trial

Ocrelizumab

• Abstract 695: Ocrelizumab, a Novel Humanized Anti-CD20 Antibody: Week 72 Results from a Phase I/II Clinical Trial in Patients with Rheumatoid Arthritis

Denosumab

• Abstract 698: Denosumab Inhibits RANKL, Reducing Progression of the Total Sharp Score and Bone Erosions in Patients With Rheumatoid Arthritis: 12-month X-Ray Results

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.